Healthcare provider profile · identity verified

Lara Kirkpatrick, MD

Family Practice · KEENE, NH · NPI 1811559198

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	230	106
Levothyroxine Sodium	Levothyroxine Sodium	197	87
Losartan Potassium	Losartan Potassium	195	96
Lisinopril	Lisinopril	154	73
Amlodipine Besylate	Amlodipine Besylate	141	60
Omeprazole	Omeprazole	131	56
Hydrochlorothiazide	Hydrochlorothiazide	130	59
Metoprolol Succinate	Metoprolol Succinate	98	49
Pantoprazole Sodium	Pantoprazole Sodium	94	35
Metformin Hcl	Metformin Hcl	80	40
Furosemide	Furosemide	78	34
Gabapentin	Gabapentin	74	32
Eliquis	Apixaban	71	25
Metoprolol Tartrate	Metoprolol Tartrate	65	28
Tamsulosin Hcl	Tamsulosin Hcl	65	29
Sertraline Hcl	Sertraline Hcl	64	32
Albuterol Sulfate Hfa	Albuterol Sulfate	54	28
Simvastatin	Simvastatin	52	29
Trazodone Hcl	Trazodone Hcl	51	23
Escitalopram Oxalate	Escitalopram Oxalate	48	20
Rosuvastatin Calcium	Rosuvastatin Calcium	48	23
Famotidine	Famotidine	47	23
Ozempic	Semaglutide	46	suppressed
Oxycodone Hcl	Oxycodone Hcl	45	11
Citalopram Hbr	Citalopram Hydrobromide	44	18
Fluticasone Propionate	Fluticasone Propionate	42	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	40	suppressed
Bupropion Xl	Bupropion Hcl	37	17
Fluoxetine Hcl	Fluoxetine Hcl	33	17
Allopurinol	Allopurinol	32	17
Hydroxyzine Hcl	Hydroxyzine Hcl	32	13
Duloxetine Hcl	Duloxetine Hcl	29	suppressed
Metformin Hcl Er	Metformin Hcl	29	17
Montelukast Sodium	Montelukast Sodium	29	16
Prednisone	Prednisone	26	16
Atenolol	Atenolol	25	16
Glimepiride	Glimepiride	24	14
Spironolactone	Spironolactone	23	11
Alendronate Sodium	Alendronate Sodium	22	suppressed
Synthroid	Levothyroxine Sodium	22	11
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Potassium Chloride	Potassium Chloride	20	12
Pregabalin	Pregabalin	20	suppressed
Finasteride	Finasteride	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	19
Alprazolam	Alprazolam	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Lorazepam	Lorazepam	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Mounjaro	Tirzepatide	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Myrbetriq	Mirabegron	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	13
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Carvedilol	Carvedilol	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	11
Valsartan	Valsartan	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Nystatin	Nystatin	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Naproxen	Naproxen	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error